PepGen appoints Afsaneh Mohebbi, Ph.D. as SVP Portfolio & Program Mgmt and Dave Borah, CFA as SVP IR & Corp Comms

PepGen Inc.

Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.
Dave Borah, CFA named SVP, Investor Relations & Corporate Communications; most recently SVP at Mural Oncology.
Appointments effective immediately; CEO cites expertise as key ahead of clinical milestones in H2 2024.
Mohebbi led Fabry drug Replagal and Firazyr approvals at Shire; Borah increased analyst coverage at Bicycle Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.